PAR Pharmaceutical

NYSE: PRX

EST Feb 8 - 25.39USD
Get stock quotes, charts, etc.
ManagementAnnual ReportsNews ReleasesPresentations/WebcastsSEC Filings

About ParProductsInvestorsMediaCustomersCareers
Home / Investors / Management

Introduction
Corporate Officers

Patrick G. LePore
Chairman,
Chief Executive Officer and President

Paul V. Campanelli
Executive Vice President and
President, Generics Division

Thomas J. Haughey
Executive Vice President,
General Counsel and
Corporate Secretary

Lawrence A. Kenyon
Executive Vice President and
Chief Financial Officer

John A. MacPhee
Executive Vice President and
President, Branded Products Division

Board of Directors

Patrick G. LePore
Chairman,
Chief Executive Officer and President

Joseph E. Smith
Lead Director
Corporate Executive Vice President
Warner-Lambert Company
Retired

John D. Abernathy
Chief Operating Officer
Patton Boggs LLP
Retired

Peter S. Knight
President
Generation Investment Management--US

Ronald M. Nordmann
Co-President
Global Health Associates, LLC

Thomas P. Rice
Principal and Co-founder
Columbia Investment LLC

Melvin Sharoky, M.D.
President and
Chief Executive Officer
Somerset Pharmaceuticals, Inc.
Retired

Auditors

  • Deloitte & Touche LLP

Governance

The business, property and affairs of Par Pharmaceutical Companies, Inc.™ (Par) are managed under the direction of the Company's Board of Directors. Members of the Board are kept informed through appropriate correspondence and discussions with the Company's executive chairman, chief executive officer, and other officers, by reviewing materials provided to them, by visiting our offices and plants, and by participating in meetings of the Board and its committees.

It is Par's policy to conform to all appropriate policies and procedures regarding the management of publicly traded companies as indicated in the Corporate Governance Guidelines. Par also requires its officers, employees, and directors to comply with the Company's Code of Ethics.

In addition, Par is committed to maintaining an effective compliance program in accordance with guidance issued by the Office of Inspector General (the "OIG Guidance") and voluntary guidelines issued by the Pharmaceutical Research and Manufacturers of America (the "PhRMA Code").

Selected committees of the board are responsible for specific Company policies and procedures:

Other corporate governance documents available for review on this web site include:

Communication with the Board

To contact the Board of Directors of Par Pharmaceutical Companies, Inc.™, please send all correspondence to:
The Board of Directors
Par Pharmaceutical Companies, Inc.™
c/o Assistant to the CEO
300 Tice Boulevard
Woodcliff Lake, NJ 07677

Correspondence may also be addressed to individual, named members of the Board of Directors at the same address.

 


Please contact investor relations with investment questions about Par.

Analyst coverage